A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
Latest Information Update: 02 Apr 2024
At a glance
- Drugs PBI-200 (Primary) ; Ritonavir
- Indications Brain cancer; Glioma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pyramid Biosciences
Most Recent Events
- 12 Mar 2024 Status changed from active, no longer recruiting to discontinued.
- 28 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Sep 2023 Planned number of patients changed from 74 to 91.